Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04922307 · ClinicalTrials.gov registry record · NA

Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer

A NA study of Kidney Cancer, sponsored by Vanderbilt University Medical Center.

Active
Registry status
NA
Development phase
240
Enrollment target
3
Study locations

NCT04922307 is a NA study of Kidney Cancer that is active but no longer recruiting, run by Vanderbilt University Medical Center. The registered enrollment target is 240 participants, below the 876-participant average among 60 other Kidney Cancer trials with a reported enrollment target (73% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04922307, a NA study of Kidney Cancer, is active but no longer recruiting, sponsored by Vanderbilt University Medical Center.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
240 participants
Enrollment target
3
Study locations

Study Summary

The Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer Trial (RESTRICT). The primary objective is to reduce the number of units of allogenic blood transfusion in locally advanced kidney cancer (≥ cT2). Secondary objectives include reduction in perioperative complications, assessment of recurrence free-survival and improving overall survival.

Conditions Studied

Interventions

  • PROCEDURE Blood Sparing Protocol
  • PROCEDURE Standard Blood Replacement

Study Locations (3)

Florida

  • H. Lee Moffitt Cancer Center - Tampa

Georgia

  • Winship Cancer Institute at Emory University - Atlanta

Tennessee

  • Vanderbilt University Medical Center - Nashville

Trial Details

FieldValue
Enrollment Target 240 participants
Start Date 2021-07-23
Est. Completion 2027-06-15
Phase NA

What the Registry Record Tells You About NCT04922307

The ClinicalTrials.gov registry entry for NCT04922307 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 876-participant average among 60 other Kidney Cancer trials with a reported enrollment target (73% lower). The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Kidney Cancer appearing as the primary indexed condition, and to 2 interventions - of which Blood Sparing Protocol is the first listed.

NCT04922307 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, Georgia, Tennessee.

Frequently Asked Questions

What is clinical trial NCT04922307 about?

NCT04922307 is a clinical study titled "Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer". The Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer Trial (RESTRICT). The primary objective is to reduce the number of units of allogenic blood transfusion in locally advanced kidney cancer (≥ cT2). Secondary objectives include reduction in perioperative complications, as...

What is the current status of trial NCT04922307?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 240 participants. The study started on 2021-07-23. Estimated completion is 2027-06-15.

What conditions does trial NCT04922307 study?

This clinical trial studies the following conditions: Kidney Cancer.

What interventions are being tested in trial NCT04922307?

The interventions under investigation include: Blood Sparing Protocol (PROCEDURE), Standard Blood Replacement (PROCEDURE).

Who is sponsoring clinical trial NCT04922307?

This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04922307 being conducted?

This trial has 3 study locations across Florida, Georgia, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Kidney Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.